Tareq Abadl: The Clinical Impact of Kell Alloimmunization
Tareq Abadl, Medical Lab Specialist, shared a post on LinkedIn:
“Kell Blood Group System: More Than Just K and k!
In Immunohematology, some blood group antigens have a major impact on transfusion safety and pregnancy outcomes.
Why is the Kell Blood Group System clinically important?
It includes several clinically significant antigens, including K, k, Kpᵃ, Kpᵇ, Jsᵃ, and Jsᵇ.
Anti-K antibodies are usually IgG and can develop following transfusion or pregnancy.
In Transfusion Medicine: Anti-K can cause acute or delayed hemolytic transfusion reactions.
Patients with Anti-K should receive K-negative, crossmatch-compatible red blood cell units.
In Pregnancy: Maternal Anti-K can cross the placenta and cause severe Hemolytic Disease of the Fetus and Newborn (HDFN).
What makes Anti-K particularly important?
Unlike many other antibodies, Anti-K can cause fetal anemia not only through red blood cell destruction but also by suppressing fetal red blood cell production (erythropoiesis).
Key Takeaway: Understanding the Kell Blood Group System is essential for accurate antibody identification, safe blood transfusion, and effective management of pregnancies at risk of HDFN.”
Other posts featuring Tareq Abadl on Hemostasis Today.
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian
-
Nov 11, 2026, 14:45ITP Is More Than a Platelet Count: Why Patient Perspectives Matter – ITP Australia and New Zealand